BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 512 filers reported holding BIO-TECHNE CORP in Q2 2021. The put-call ratio across all filers is 2.08 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,276,664 | +17.4% | 17,818 | +15.4% | 0.12% | +7.8% |
| Q1 2024 | $1,087,084 | -5.4% | 15,444 | +3.7% | 0.12% | -10.2% |
| Q4 2023 | $1,149,164 | +19.7% | 14,893 | +5.6% | 0.13% | +6.7% |
| Q3 2023 | $960,231 | +148.2% | 14,107 | +197.7% | 0.12% | +144.9% |
| Q2 2023 | $386,870 | +26.5% | 4,739 | +15.0% | 0.05% | +22.5% |
| Q1 2023 | $305,786 | -7.5% | 4,122 | +3.4% | 0.04% | -13.0% |
| Q4 2022 | $330,447 | +18.4% | 3,987 | +305.6% | 0.05% | +4.5% |
| Q3 2022 | $279,000 | -20.5% | 983 | -2.9% | 0.04% | -17.0% |
| Q2 2022 | $351,000 | -15.0% | 1,012 | +6.1% | 0.05% | -3.6% |
| Q1 2022 | $413,000 | +0.5% | 954 | +20.2% | 0.06% | +5.8% |
| Q4 2021 | $411,000 | +6.8% | 794 | 0.0% | 0.05% | -1.9% |
| Q3 2021 | $385,000 | +9.1% | 794 | +1.1% | 0.05% | +10.4% |
| Q2 2021 | $353,000 | +14.2% | 785 | -19.3% | 0.05% | +4.3% |
| Q4 2020 | $309,000 | +29.3% | 973 | +0.9% | 0.05% | +15.0% |
| Q3 2020 | $239,000 | 0.0% | 964 | +6.4% | 0.04% | -7.0% |
| Q2 2020 | $239,000 | +94.3% | 906 | +40.0% | 0.04% | +53.6% |
| Q1 2020 | $123,000 | -15.8% | 647 | -2.7% | 0.03% | -33.3% |
| Q4 2019 | $146,000 | -10.4% | 665 | -20.1% | 0.04% | -14.3% |
| Q3 2019 | $163,000 | +13.2% | 832 | +20.6% | 0.05% | +2.1% |
| Q2 2019 | $144,000 | +620.0% | 690 | +411.1% | 0.05% | +500.0% |
| Q4 2018 | $20,000 | -28.6% | 135 | 0.0% | 0.01% | -27.3% |
| Q3 2018 | $28,000 | – | 135 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
| Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
| Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
| STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
| Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
| Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
| Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
| DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
| Westwind Capital | 27,946 | $9,687,000 | 3.17% |
| MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |